Keywords: etanercept, adalimumab, injection site reaction, adverse event reporting system. This study was the first to evaluate the relationship between aging and ISR using the FAERS database. Furthermore, we found that crude RORs for ETN + methotrexate (MTX) combination therapy and ADA + MTX combination therapy were lower than those for the respective monotherapies. The adjusted RORs for ETN* ≥ 70 and ADA* ≥ 70 groups were the lowest among the age-stratified groups undergoing the respective monotherapies. Adjusted reporting odds ratios (RORs) (95% Confidence Intervals) were obtained for interaction terms for age-stratified groups treated with etanercept (ETN) and adalimumab (ADA). The FAERS database contains 7,561,254 reports from January 2004 to December 2015. In order to improve understanding of the risk factors contributing to the induction of ISR, we evaluated the association between TNF-α inhibitors and ISR by applying a logistic regression model to age-stratified data obtained from the Food and Drug Administration Adverse Event Reporting System (FAERS) database. In order to alleviate pain and other symptoms, early countermeasures must be taken against this adverse event. ISR gives rise to patient stress, nervousness, and a decrease in quality of life (QoL). However, the administration of these drugs carries the risk of inducing injection site reaction (ISR). Tumor necrosis factor-α (TNF-α) inhibitors are increasingly being used as treatment for rheumatoid arthritis (RA). Select the file that you have just downloaded and select import option Reference Manager (RIS).
#Age calculation in filemaker pro 6 download#
Available fromĬlick on Go to download the file.
Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015.
Matsui T, Umetsu R, Kato Y, Hane Y, Sasaoka S, Motooka Y, Hatahira H, Abe J, Fukuda A, Naganuma M, Kinosada Y, Nakamura M.
0 kommentar(er)
